Document Detail


Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily-pretreated Relapsed or Refractory Multiple Myeloma.
MedLine Citation:
PMID:  22881043     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Background The combination of lenalidomide, bortezomib, and dexamethasone (RVD) has shown excellent efficacy in relapsed or refractory (RRMM) multiple myeloma patients. The aim of our study was to assess the efficacy and toxicity profile of RVD for patients with advanced RRMM. Methods We retrospectively reviewed the records of all RRMM patients treated with RVD between 03/09-12/11. Thirty patients received ≥ 1 full cycle of RVD. Primary endpoints were overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results After a median of 5 cycles (1-16), VGPR was seen in 10%, PR in 36.7% and SD in 13.3% (ORR of 46.7%). Disease progression occurred in 21 patients at a median of 3 months (range 1.41-4.59). Eight patients (26%) experienced grade 3/4 adverse events, including anemia, neutropenia, muscle weakness, and pneumonia. No patient experienced worsening peripheral neuropathy. Conclusions Although RVD has been previously shown to be effective in RRMM, the ORR and PFS we observed were affected by very advanced disease status and heavy prior exposure to novel agents. Nevertheless, six of these RRMM patients experienced a benefit of ≥6 months, suggesting synergism of this immunomodulatory derivative/proteasome inhibitor combination and/or re-establishment of drug sensitivity by an emergent myeloma clone.
Authors:
Victor H Jimenez-Zepeda; Donna E Reece; Suzanne Trudel; Christine Chen; Rodger Tiedemann; Vishal Kukreti
Related Documents :
434333 - Feasibility of integration of modalities in melanomas and sarcomas.
22681643 - Randomized phase ii trial of urethral sparing intensity modulated radiation therapy in ...
1827303 - Is breast conservation after local recurrence feasible?
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-10
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Light-Triggered Reversible Supramolecular Transformations of Multi-Bisthienylethene Hexagons.
Next Document:  Towards a better understanding of the legibility bias in performance assessments: The case of gender...